LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, inaugurates today an investment of more than EUR 22m in a brand new 9,500 m2 extension to its state-of-the-art food testing laboratory in Nantes, France, next to the Company’s first-ever laboratory.
The newly-completed facility brings total size of the campus to 23,640 m2, making it the largest independent food testing laboratory site in Europe, including 4,200 m2 of spare capacity which can be readily used for future growth. The new laboratory extension was launched in response to the strong growth experienced and expected by Eurofins. This new fully-modernized state-of-the art site will help Eurofins better serve the food industry in France, as well as throughout Europe, and provide a solid basis to support the Group’s strong acceleration in market share gains.
The new laboratory layout is expected to significantly improve efficiency, scalability and turn-around times (TAT). Therefore, the extension project should benefit Eurofins’ customers, who will continue to receive a high-quality service with lower TAT. The extension will also increase the breadth of service offerings of the various Eurofins companies present at this site. These services include, among others, nutrition analyses, molecular biology, water testing, asbestos testing, air testing, soil testing, DNA sequencing, contaminants testing and authenticity testing.
Eurofins Nantes contributes to ca. 45% of Eurofins’ Food Testing revenues in France, processing nearly 1.5 million samples and performing 5 million analyses per year. This extension project reflects Eurofins’ strong commitment to continuously developing and growing its state-of-the art network of modern world class laboratories.
Comment from François Vigneau, General Manager for Eurofins Food Testing South Europe: “Eurofins is proud to have completed the Nantes extension project as planned. It is remarkable that in just 30 years, Eurofins Nantes has transitioned from a small beverages testing specialist to a global leader in food, pharmaceuticals and environmental testing. This large investment in laboratory expansion is another demonstration of the Group’s strong commitment to always offering its clients faster, more sensitive and more cost-effective advanced testing services.”
For more information, please visit www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 41 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.